<DOC>
	<DOCNO>NCT00416351</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , clofarabine , work different way stop growth cancer cell , either kill cell stop dividing . PURPOSE : This phase I/II trial study side effect best dose clofarabine see well work treat patient T-cell natural killer-cell lymphoma relapse respond previous treatment .</brief_summary>
	<brief_title>Clofarabine Treating Patients With T-Cell Natural Killer-Cell Non-Hodgkin 's Lymphoma That Has Relapsed Not Responded Previous Treatment</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose clofarabine patient relapse refractory T-cell natural killer-cell lymphoma . - Determine toxicity drug patient . - Determine , preliminarily , efficacy drug , term response rate , patient . OUTLINE : This phase I , non-randomized , dose-escalation study follow open-label , phase II study . - Phase I : Patients receive clofarabine IV 1 hour daily day 1-3 . Treatment repeat every 21 day 2 course absence disease progression unacceptable toxicity . Patients achieve stable disease partial response ( PR ) complete response ( CR ) may receive 2 additional course treatment . Patients PR CR complete 4 course therapy may receive 2 additional course . Cohorts 1-6 patient receive escalate dos clofarabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 6 patient experience dose-limiting toxicity . - Phase II : Patients receive clofarabine phase I MTD determine phase I . After completion study treatment , patient follow every 3 month 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm Tcell natural killer ( NK ) cell lymphoma , include follow subtypes : Blastic NKcell lymphoma T/NKcell lymphoma/leukemia Adult Tcell lymphoma/leukemia Tcell prolymphocytic leukemia Tlymphoblastic lymphoma Peripheral Tcell lymphoma , otherwise specify Angioimmunoblastic Tcell lymphoma Anaplastic large cell lymphoma Transformed mycosis fungoides Subcutaneous panniculitislike Tcell lymphoma Nasal T/NKcell lymphoma Enteropathytype Tcell lymphoma Hepatosplenic gamma/delta Tcell lymphoma Relapsed refractory disease , meet follow criterion : Must treat prior cytotoxic chemotherapy and/or monoclonal antibody therapy No standard curative treatment exist Allogeneic bone marrow transplantation consider standard curative treatment Evaluable disease ( Phase I ) Measurable disease , define nodal site mass lesion ≥ 1.5 cm long transverse diameter physical exam CT scan OR measurable extranodal site &gt; 1 cm ( Phase II ) Patients evaluable blood marrowbased disease eligible PATIENT CHARACTERISTICS : ECOG performance status 02 Absolute neutrophil count ≥ 1,500/mm³ ( Phase I ) Absolute neutrophil count ≥ 500/mm³ ( Phase II ) Platelet count ≥ 100,000/mm³ ( Phase I ) Platelet count ≥ 50,000/mm³ ( Phase II ) Creatinine &lt; 2.0 mg/dL* Bilirubin ≤ 2.0 time upper limit normal ( ULN ) * AST ALT ≤ 2.5 time ULN* No active infection require antibiotic No New York Heart Association class III IV congestive heart failure No known HIV positivity No active malignancy require therapy No serious lifethreatening condition deem unacceptable principal investigator Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception NOTE : *Unless due lymphoma patient enter phase II portion study PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 3 week since prior therapy , include follow : Interferon Antibody therapy Retinoids Other nonchemotherapeutic treatment Concurrent stabledose corticosteroid allow No colonystimulating factor therapy first course study therapy</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>small intestine lymphoma</keyword>
</DOC>